Skip to main content
Clinical Trials/NCT04559256
NCT04559256
Completed
Not Applicable

Transcatheter Tricuspid Valve Interventions and Right Ventricular Function: Evaluation with Cardiopulmonary Exercise Testing

Heart and Diabetes Center North-Rhine Westfalia1 site in 1 country30 target enrollmentJanuary 1, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Tricuspid Regurgitation
Sponsor
Heart and Diabetes Center North-Rhine Westfalia
Enrollment
30
Locations
1
Primary Endpoint
Influence of transcatheter tricuspid intervention on peak oxygen uptake
Status
Completed
Last Updated
last year

Overview

Brief Summary

Tricuspid regurgitation (TR), which in close to 90% of cases is functional as a consequence of left-sided heart failure, left heart valve abnormalities or pulmonary (vascular) disease, is associated with adverse patient outcomes . Due to the increased risk of surgical tricuspid valve repair or replacement compared to surgery in left-sided valve disease TR is often undertreated. Treatment options for the tricuspid valve have so far been limited. Conservative therapy over longer. periods usually results in refractoriness to diuretic treatment. Surgical therapy is associated with a high rate of in-hospital mortality (8.8%), the cause of which is not yet fully understood but may partly be explained by the hemodynamic challenge that cardiopulmonary bypass imposes on the often already-dysfunctional right ventricle. Recently, transcatheter strategies have been developed and have shown promising results. Despite the promising data it has so far not be determined objectively whether interventional treatment of isolated tricuspid regurgitation improves exercise capacity and what role right ventricular function plays in this setting.

Registry
clinicaltrials.gov
Start Date
January 1, 2020
End Date
December 1, 2024
Last Updated
last year
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Heart and Diabetes Center North-Rhine Westfalia
Responsible Party
Principal Investigator
Principal Investigator

Muhammed Gerçek

Principal Investigator

Heart and Diabetes Center North-Rhine Westfalia

Eligibility Criteria

Inclusion Criteria

  • Chronic tricuspid regurgitation 2+ to 4+ on a scale of 4+ (moderate to severe) with annular diameter ≥ 40 mm with valve systolic pulmonary pressure (sPAP) ≤ 60 mmHg
  • New York Heart Association (NYHA) Class II-IV
  • Symptomatic despite Guideline Directed Medical Therapy (GDMT); at minimum patient on diuretic regimen
  • Left ventricular ejection fraction ≥ 30%
  • Symptomatic despite Guideline Directed Medical Therapy (GDMT); at minimum patient on diuretic regimen
  • The local site Heart Team concur that surgery will not be offered as a treatment option
  • Written informed consent in accordance with Good Clinical Practice (GCP) and local legislation

Exclusion Criteria

  • Inability to perform cardiopulmonary exercise test
  • Aortic, mitral and/or pulmonic valve stenosis and/or regurgitation ≥ moderate
  • Previous tricuspid valve repair or replacement
  • Severe precapillary pulmonary hypertension (PVR\>6 WE)
  • Cerebrovascular accident (CVA) within the past 6 months
  • Presence of trans-tricuspid pacemaker or defibrillator leads which cause impingement of the tricuspid valve leaflet as evaluated by echocardiography
  • Subject is on chronic dialysis and/or anemia (Hb \< 9 g/L)
  • Myocardial infarction or known unstable angina within 30 days prior to the index procedure
  • Any percutaneous coronary intervention or transcatheter valvular intervention within 30 days prior to the index procedure or planned 3 months post the index procedure
  • Previous tricuspid valve repair or replacement

Outcomes

Primary Outcomes

Influence of transcatheter tricuspid intervention on peak oxygen uptake

Time Frame: 3 month

Changes on maximal oxygen uptake (peak VO2) assessed by cardiopulmonary exercise testing (CPET, spiroergometry) after transcatheter tricuspid intervention

Influence of transcatheter tricuspid intervention on duration of submaximal exercise tolerance

Time Frame: 3 month

Changes on the duration of submaximal exercise tolerance assessed by exercise time during high-intensity constant-work rate endurance tests (CWRET) after transcatheter tricuspid intervention

Secondary Outcomes

  • Prevalence of moderate to severe or severe tricuspid regurgitation(3 month)
  • Rehospitalization rate for heart failure(3 month)
  • Influence of transcatheter tricuspid intervention on the minute ventilation/carbon dioxide production slope in the cardiopulmonary exercise testing(3 month)
  • Influence of transcatheter tricuspid intervention on the left an right ventricle(3 month)
  • Prevalence of oscillatory respiration pattern(3 month)
  • Influence of transcatheter tricuspid intervention on NYHA class(3 month)
  • Influence of transcatheter tricuspid intervention on serum N terminal-proBNP level(3 month)
  • Exercise Testing with 6 min walking test(3 month)
  • Influence of transcatheter tricuspid intervention on quality of life(3 month)

Study Sites (1)

Loading locations...

Similar Trials